…
Ascend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tablets, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Royale, High Wired, Effin', Miss Grass, Lowell Smokes, Flower by Edie Parker, 1906, AiroPro, and Miss Grass brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores, and third-party licensed retail cannabis stores. The company was formerly known as Ascend Wellness Holdings, LLC and changed its name to Ascend Wellness Holdings, Inc. in April 2021. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in Rochelle Park, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Ascend Wellness Holdings Inc is a U.S. multi-state cannabis operator that cultivates, processes and sells medical and adult-use cannabis through owned cultivation and retail assets. Long-term growth drivers include expansion of retail footprint, rising consumer adoption as more states legalize, and scale benefits from vertical integration. Its diversified state presence and integrated operations may support revenue growth and market share gains.
Key investment risks include federal illegality affecting banking and taxation, state-level regulatory or licensing changes, intense competition among multi-state operators, and capital-intensive operations that could strain margins or financing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -66.81M | -39.82M | -14.76M | -39.21M | -80.94M |
| Minority interest | - | - | - | 0.00M | 0.00M |
| Net income | -118.19M | -84.99M | -48.21M | -80.90M | -122.66M |
| Selling general administrative | 129.39M | 144.48M | 129.43M | 137.09M | 116.67M |
| Gross profit | 169.68M | 184.21M | 155.12M | 134.56M | 135.97M |
| Reconciled depreciation | 75.59M | 68.12M | 60.04M | 38.24M | 23.58M |
| Ebit | - | - | - | -6.77M | -16.95M |
| Ebitda | - | - | - | 29.29M | 6.63M |
| Non operating income net other | - | - | - | 0.76M | 0.26M |
| Operating income | -0.76M | 4.75M | -3.85M | -7.53M | -17.20M |
| Interest expense | 51.17M | 39.79M | 36.98M | 32.44M | 63.99M |
| Tax provision | 51.38M | 45.17M | 33.45M | 41.69M | 41.72M |
| Net interest income | -51.17M | -39.79M | -36.98M | -30.26M | -63.99M |
| Non recurring | - | - | - | 5.00M | 36.51M |
| Income tax expense | - | - | - | 41.69M | 41.72M |
| Total revenue | 500.58M | 561.60M | 518.59M | 405.93M | 332.38M |
| Total operating expenses | 501.34M | 556.85M | 522.43M | 142.09M | 153.18M |
| Cost of revenue | 330.90M | 377.39M | 363.47M | 271.36M | 196.41M |
| Total other income expense net | -14.89M | -4.78M | 26.07M | -6.77M | -36.86M |
| Net income from continuing ops | -118.19M | -84.99M | -48.21M | -80.90M | -122.66M |
| Net income applicable to common shares | - | - | - | -80.90M | -122.66M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 907.93M | 900.43M | 919.55M | 872.16M | 723.44M |
| Intangible assets | 196.07M | 205.50M | 221.45M | 221.09M | 59.27M |
| Other current assets | 2.34M | 0.35M | 2.50M | 162.72M | 171.76M |
| Total liab | 954.55M | 828.63M | 776.68M | 708.75M | 546.96M |
| Total stockholder equity | -46.62M | 71.80M | 142.87M | 163.41M | 176.48M |
| Deferred long term liab | - | - | - | 33.61M | 1.42M |
| Other current liab | 7.07M | 5.06M | 6.77M | 8.35M | 7.82M |
| Common stock | - | - | - | 0.19M | 0.17M |
| Capital stock | 0.20M | 0.20M | 0.21M | 0.19M | 0.17M |
| Retained earnings | -518.55M | -400.36M | -315.36M | -267.15M | -186.25M |
| Other liab | - | - | - | 48.68M | 1.42M |
| Good will | 58.45M | 49.60M | 47.54M | 44.37M | 42.97M |
| Other assets | - | - | - | 19.28M | 19.57M |
| Cash | 85.68M | 88.25M | 72.51M | 74.15M | 155.48M |
| Total current liabilities | 109.01M | 144.54M | 92.69M | 110.95M | 117.39M |
| Net debt | 218.72M | 220.17M | 236.21M | 256.48M | 103.31M |
| Short term debt | - | - | - | 11.33M | 27.94M |
| Short long term debt | 13.29M | 73.88M | 11.15M | 11.33M | 27.94M |
| Property plant equipment | - | - | - | 388.67M | 239.66M |
| Total current assets | 208.95M | 229.38M | 228.86M | 198.74M | 258.01M |
| Net tangible assets | - | - | - | -57.68M | 117.21M |
| Net receivables | 27.02M | 36.54M | 28.30M | 36.81M | 31.68M |
| Long term debt | 291.10M | 234.54M | 297.56M | 319.30M | 230.85M |
| Inventory | 84.71M | 89.55M | 95.29M | 97.53M | 65.59M |
| Accounts payable | 20.91M | 26.41M | 34.69M | 91.27M | 81.64M |
| Common stock total equity | - | - | - | 0.19M | 0.17M |
| Retained earnings total equity | - | - | - | -267.15M | -186.25M |
| Non currrent assets other | 14.99M | 16.43M | 23.06M | 279.86M | 19.57M |
| Non current assets total | 698.98M | 671.05M | 690.69M | 500.95M | 298.93M |
| Capital lease obligations | 325.23M | 272.69M | 264.75M | 232.45M | 199.96M |
| Long term debt total | - | - | - | 319.30M | 230.85M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -37.20M | -59.89M | -2.44M | -2.65M |
| Change to liabilities | - | - | - | 11.80M | 25.41M |
| Total cashflows from investing activities | - | - | - | -114.25M | -113.23M |
| Net borrowings | 8.58M | 0.73M | -23.56M | 76.22M | 171.46M |
| Total cash from financing activities | 5.11M | -20.35M | -17.08M | 71.28M | 252.35M |
| Change to operating activities | - | - | - | 7.92M | -19.64M |
| Net income | -118.19M | -84.99M | -48.21M | -80.90M | -122.66M |
| Change in cash | -2.58M | 15.75M | -1.64M | -81.33M | 97.38M |
| Begin period cash flow | 88.25M | 72.51M | 74.15M | 155.48M | 58.10M |
| End period cash flow | 85.68M | 88.25M | 72.51M | 74.15M | 155.48M |
| Total cash from operating activities | 38.05M | 73.29M | 75.33M | -38.36M | -41.74M |
| Issuance of capital stock | 0.00M | 0.00M | 7.00M | 0.00M | 86.06M |
| Depreciation | 75.59M | 68.12M | 60.04M | 37.11M | 22.22M |
| Other cashflows from investing activities | - | - | - | -30.17M | -22.16M |
| Change to inventory | -10.71M | 1.81M | -14.88M | -43.81M | -36.50M |
| Change to account receivables | 7.92M | -8.24M | -14.20M | -6.48M | -1.34M |
| Sale purchase of stock | -2.31M | -2.75M | 0.00M | - | 81.91M |
| Other cashflows from financing activities | - | - | - | -4.95M | -1.01M |
| Change to netincome | - | - | - | 35.44M | 62.75M |
| Capital expenditures | 37.96M | 35.23M | 40.19M | 81.64M | 88.43M |
| Change receivables | - | - | - | -6.48M | -1.34M |
| Cash flows other operating | - | - | - | 8.49M | 8.38M |
| Cash and cash equivalents changes | - | - | - | -81.33M | 97.38M |
| Change in working capital | 64.08M | 63.32M | 26.18M | -31.14M | -32.84M |
| Stock based compensation | 2.45M | 18.61M | 19.78M | 18.98M | 23.09M |
| Other non cash items | 22.06M | 20.52M | 30.04M | 21.87M | 70.12M |
| Free cash flow | 0.09M | 38.06M | 35.14M | -164.25M | -130.17M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AAWH Ascend Wellness Holdings Inc |
-0.01 3.99% |
0.32 | - | 10.88 | 0.22 | 5.95 | 1.43 | 10.11 |
| MKKGY Merck KGaA ADR |
-0.68 2.09% |
31.83 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
163.45 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.38 1.77% |
21.79 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.05 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Ascend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tablets, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Royale, High Wired, Effin', Miss Grass, Lowell Smokes, Flower by Edie Parker, 1906, AiroPro, and Miss Grass brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores, and third-party licensed retail cannabis stores. The company was formerly known as Ascend Wellness Holdings, LLC and changed its name to Ascend Wellness Holdings, Inc. in April 2021. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in Rochelle Park, New Jersey.
| Name | Title | Year Born |
|---|---|---|
| Mr. Abner B. Kurtin | Founder & Exec. Chairman of The Board | 1967 |
| Mr. Francis Perullo | Co-Founder, Interim Co-CEO, Pres, Chief Strategy Officer, Sec. & Director | 1977 |
| Mr. Daniel Neville | Interim Co-CEO, CFO, Treasurer & Director | 1986 |
| Mr. David Gacom | Chief Operating Officer | NA |
| Mr. Roman Nemchenko | Sr. VP & Chief Accounting Officer | NA |
| Ms. Rebecca Conti Koar B.Sc. | Sr. VP of Investor Relations | NA |
| Ms. Robin Debiase | Chief People Officer | 1971 |
| Mr. Christopher Melillo | Chief Revenue Officer | 1974 |
| Jason Liotta | Sr. VP of Fin. | NA |
| Mr. Brian Miesieski | Chief Brand Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.